Chronic traumatic encephalopathy.


Journal

Neuro-Chirurgie
ISSN: 1773-0619
Titre abrégé: Neurochirurgie
Pays: France
ID NLM: 0401057

Informations de publication

Date de publication:
May 2021
Historique:
received: 14 12 2020
revised: 07 02 2021
accepted: 13 02 2021
pubmed: 24 2 2021
medline: 22 6 2021
entrez: 23 2 2021
Statut: ppublish

Résumé

Chronic traumatic encephalopathy (CTE) is a neurodegenerative disease linked to repeated traumatic brain injury (TBI). This disorder is mainly observed in subjects at risk for brain traumatisms including boxers, American football and European football (soccer) players, as well as war veterans. Neuropathological findings are marked by abnormally phosphorylated tau accumulations at the depth of cerebral sulci, as well as TDP43, Aβ and α-synuclein positive staining. It has been described 3 clinical variants: the behavioural/mood variant, the cognitive variant and the mixed behavioural/cognitive variant. Cerebral MRI revealed signs of diffuse atrophy with abnormal axonal findings using the diffusion tensor imaging methods. Cerebral PET tau revealed increased standardised uptake value ratio (SUVR) levels in various brain regions of CTE patients compared to controls. The place of CTE among other neurodegenerative diseases is still debated. The focus of CTE management must be on prevention. The best way to prevent CTE in athletes is to put in place strict and appropriate measures by physicians. An individual with concussion should not be allowed to play again immediately (and sometimes never) in cases of abnormal neurological symptoms or imaging abnormalities.

Identifiants

pubmed: 33621530
pii: S0028-3770(21)00042-4
doi: 10.1016/j.neuchi.2021.02.003
pii:
doi:

Substances chimiques

Biomarkers 0
MAPT protein, human 0
tau Proteins 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

290-294

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

J Hugon (J)

Centre de neurologie cognitive, AP-HP, Hôpital Lariboisière FW, Université de Paris et INSERM U1144, 75010 Paris, France. Electronic address: jacques.hugon@aphp.fr.

C Hourregue (C)

Centre de neurologie cognitive, AP-HP, Hôpital Lariboisière FW, Université de Paris et INSERM U1144, 75010 Paris, France.

E Cognat (E)

Centre de neurologie cognitive, AP-HP, Hôpital Lariboisière FW, Université de Paris et INSERM U1144, 75010 Paris, France.

M Lilamand (M)

Centre de neurologie cognitive, AP-HP, Hôpital Lariboisière FW, Université de Paris et INSERM U1144, 75010 Paris, France.

B Porte (B)

Centre de neurologie cognitive, AP-HP, Hôpital Lariboisière FW, Université de Paris et INSERM U1144, 75010 Paris, France.

F Mouton-Liger (F)

Centre de neurologie cognitive, AP-HP, Hôpital Lariboisière FW, Université de Paris et INSERM U1144, 75010 Paris, France.

J Dumurgier (J)

Centre de neurologie cognitive, AP-HP, Hôpital Lariboisière FW, Université de Paris et INSERM U1144, 75010 Paris, France.

C Paquet (C)

Centre de neurologie cognitive, AP-HP, Hôpital Lariboisière FW, Université de Paris et INSERM U1144, 75010 Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH